Buy Braftovi Online

Braftovi is an oral cancer medicine containing encorafenib, a targeted BRAF kinase inhibitor. It can be ordered online, with current Braftovi price information shown during checkout and dose or strength selection matched to your clinician’s directions. It is commonly used as part of a combination regimen for certain cancers with a confirmed BRAF V600 mutation.

Braftovi is supplied as capsules and is used with other anti-cancer medicines rather than as a stand-alone treatment in the main labeled settings. People often compare Braftovi cost, capsule strength, and Braftovi from Canada service details because treatment may continue over time and may involve multiple medicines. Our ordering process helps you choose the product strength displayed for sale and review the total quantity against the treatment plan you have been given.

Braftovi Price, Capsule Strengths, and Ordering

The Braftovi price you see can vary by capsule strength, quantity, sourcing, and any cash-pay considerations. When reviewing Braftovi capsules price, check whether the amount shown reflects the capsule strength or the total daily amount your regimen requires. This is especially important for Braftovi 75mg capsules, because one capsule strength does not by itself describe the full daily dose.

Braftovi is available in capsule strengths that may include 50 mg and 75 mg. Encorafenib 75mg capsules are often referenced because they can be used to build the total daily amount directed for specific combination treatment plans. Availability of a specific strength can vary, so choose from the strengths shown during ordering and keep the dose consistent with the instructions from your oncology team.

For U.S. customers using a Canada-to-US service, Braftovi Canadian pricing may be helpful when comparing self-pay oncology medication costs. The medicine may ship with prompt, express shipping after order details are complete. Avoid comparing only the per-capsule number; the more useful comparison is the total amount needed for the full treatment period.

Quick tip: Keep a written list of capsule strength, daily capsule count, and combination medicines so refills match your regimen.

What Braftovi Treats

Braftovi is used for adults with certain cancers that have a BRAF V600 mutation, which is a specific genetic change in the tumor. In unresectable or metastatic melanoma, it is used in combination with a MEK inhibitor such as binimetinib. In metastatic colorectal cancer with a BRAF V600E mutation, it is used with an EGFR inhibitor such as cetuximab, depending on the treatment setting.

The mutation result matters. Braftovi is not intended for tumors that do not have the relevant BRAF mutation. Your cancer team usually confirms mutation status through tumor testing before selecting a targeted regimen. For condition background, explore our melanoma information and colorectal cancer information.

Braftovi is not traditional chemotherapy and it is not immunotherapy. It is a targeted therapy, meaning it is designed to interfere with a cancer-growth signal that is active in tumors with certain BRAF changes. That distinction matters because side effects, monitoring, and combination choices differ from chemotherapy or immune checkpoint inhibitor treatment.

How Encorafenib Works

Encorafenib blocks mutated BRAF kinase activity. BRAF is part of the MAPK pathway, a chain of signals that can tell cells to grow and divide. When the BRAF V600 mutation is present, this pathway may stay overactive, supporting cancer growth.

Braftovi’s mechanism of action is one reason it is paired with other medicines. In melanoma, using a BRAF inhibitor with a MEK inhibitor targets related steps in the same pathway. In colorectal cancer, adding an EGFR inhibitor helps address another signaling route that can drive tumor activity. The exact regimen depends on cancer type, prior therapy, tolerability, and test results.

References to Encorafenib Pfizer usually point to manufacturer information for the branded product. The practical buying decision remains the same: confirm the active ingredient, capsule strength, and total regimen your care team intends you to use.

Dosing Basics and Daily Use

Braftovi is taken by mouth, usually once daily, as part of a combination regimen. Label-directed dosing differs by cancer type and by the medicine used with it. For example, melanoma regimens may use encorafenib with binimetinib, while colorectal cancer regimens may use encorafenib with cetuximab.

Swallow capsules whole with water. Braftovi may be taken with or without food, and taking it at about the same time each day can make the routine easier to remember. If vomiting occurs after a dose, do not take an extra dose unless your care team gives different instructions. Dose holds, reductions, or restarts should be handled by the treating clinician.

The term Braftovi 75 mg dose can be confusing. The 75 mg amount refers to a capsule strength, not necessarily the full daily dose. Your total daily amount may require more than one capsule, and the combination partner may have a separate schedule.

Missed Dose, Monitoring, and Treatment Expectations

If you miss a dose, follow the instructions provided with your treatment plan or the official label. In general, missed-dose guidance depends on how close you are to the next scheduled dose. Do not double up to make up for a missed dose unless your oncology team specifically instructs you to do so.

Your care team will monitor how the cancer responds with exams, imaging, labs, and symptom review. Skin checks are also important because BRAF inhibitor therapy can be associated with new skin growths or skin cancers. Eye symptoms, heart rhythm concerns, liver lab changes, bleeding, and severe skin reactions need prompt medical attention.

Questions about survival rates or life expectancy with BRAF-mutated cancer cannot be answered by the medicine name alone. Outcomes depend on cancer type, stage, mutation status, prior treatments, overall health, and whether the cancer responds. Ask your oncologist what the treatment goal is for your exact diagnosis, and how response will be measured.

Side Effects, Warnings, and Interactions

Common side effects of Braftovi can include fatigue, nausea, vomiting, diarrhea, abdominal pain, joint or muscle pain, headache, rash, dry skin, and hair changes. Some people also experience redness, sensitivity to sunlight, or other skin changes. Protective clothing and broad-spectrum sunscreen may be recommended during treatment.

• Skin: rash, dryness, acne-like changes, photosensitivity, or new skin lesions.
• Digestive system: nausea, vomiting, diarrhea, reduced appetite, or abdominal discomfort.
• Muscles and joints: aches, stiffness, or joint pain.
• General symptoms: fatigue, headache, fever, or feeling unwell.

Serious risks may include new primary skin cancers, bleeding, liver problems, eye problems including retinal disorders, QT prolongation, and harm to an unborn baby. Combination medicines add their own safety profiles. MEK inhibitors can add risks such as heart, eye, and muscle-related effects, while EGFR inhibitors are often associated with rash and infusion-related concerns.

Encorafenib is affected by CYP3A4, an enzyme involved in drug metabolism. Strong CYP3A4 inhibitors may increase encorafenib exposure, while strong CYP3A4 inducers may reduce it. Examples can include certain antifungals, macrolide antibiotics, seizure medicines, rifampin, and St. John’s wort. Grapefruit products are generally avoided. Tell your care team about all medicines, vitamins, and herbal products you take.

Contact a healthcare professional urgently for vision changes, fainting, chest pain, severe bleeding, black or bloody stools, severe abdominal pain, yellowing of the skin or eyes, or a rapidly worsening rash. People with heart rhythm concerns, liver impairment, eye disease, or pregnancy potential may need additional monitoring or a different plan.

Storage and Travel

Store Braftovi capsules at room temperature in the original container, tightly closed, and protected from moisture. Keep the medicine away from children and pets. Do not use capsules that appear damaged, wet, or altered.

For travel, keep the medicine in carry-on luggage with dosing instructions and the original labeled container when possible. Bring enough supply for the trip plus a buffer in case plans change. If time zones affect the dosing schedule, ask your oncology team how to keep the interval consistent.

Because Braftovi is often part of a multi-drug regimen, keep combination medicines organized separately and label reminders clearly. A dosing diary can help you record daily capsules, missed doses, side effects, and questions for the next appointment.

How Braftovi Compares With Related Cancer Medicines

Treatment for BRAF-mutated melanoma or colorectal cancer is individualized. Braftovi is a BRAF inhibitor, while its usual combination partners target different parts of cancer signaling. The best choice depends on cancer type, mutation test results, previous treatment, organ function, and the risks you are willing to accept.

For melanoma, BRAF and MEK inhibitor combinations are commonly discussed because dual pathway targeting may help control signaling more effectively than targeting one step alone. For colorectal cancer, EGFR-directed therapy is part of the labeled combination approach in specific BRAF V600E-mutant disease settings.

You can browse broader cancer medicines or read category updates in our cancer articles. If country-of-origin matters for planning, our Canada-origin medicines section may help you understand sourcing categories.

Questions to Ask Before Starting or Refilling

Before starting or refilling Braftovi, ask your care team to confirm the exact cancer type, BRAF mutation result, daily capsule count, and each combination medicine. Also ask what symptoms should trigger a same-day call. Clear instructions reduce confusion when several cancer medicines are used together.

• Is my tumor confirmed to have a BRAF V600E or V600K mutation?
• Which medicine is being combined with Braftovi, and on what schedule?
• What labs, skin checks, heart monitoring, or eye exams do I need?
• Which side effects should I report right away?
• Do any of my current medicines interact with encorafenib?
• What should I do if I miss a dose or vomit after taking it?
• How will we decide whether treatment is working?

Why it matters: Targeted therapy works best when the dose, mutation result, and combination plan are all aligned.

Authoritative Sources

Official prescribing information

Manufacturer patient information

European Medicines Agency product information

This content is for informational purposes only and is not a substitute for professional medical advice.